Hypophosphatemia

23 registered clinical trials studyying Hypophosphatemia — 5 currently recruiting.

Status	Trial	Sponsor	Phase
Not Yet Recruiting	Protocolised Management of Phosphate Replacement Trial NCT07288944	Caboolture Hospital	N/A
Recruiting	Enteral Supplementation With Sodium Dihydrogen Phosphate and Disodium Hydrogen Phosphate Granules for the Trea NCT07233889	Union Hospital, Tongji Medical College, Huazhong University of Science and Technology	N/A
Not Yet Recruiting	Evaluation of Dipyridamole in Preventing Post-Transplant Hypophosphatemia in Kidney Transplant Recipients NCT06824454	Stanford University	Phase 2
Recruiting	Effect of Hypophosphatemia on Neuro-excursion Efficiency During Mechanical Ventilator Weaning NCT06754670	Peking Union Medical College	—
Recruiting	IV Iron-induced Hypophosphatemia After RYGB NCT06350955	Lucie Favre	Phase 4
Completed	Metabolic Pathway Analysis in Intensive Care Unit Patients With Refeeding Syndrome NCT06344546	Karolinska University Hospital	—
Completed	Validation of the GIDS and Description of Phosphate Disorders NCT05909722	University of Tartu	—
Active Not Recruiting	Effects of Treatments for Anemia and Iron Deficiency on the Electrolyte Balance in Lung Transplant Recipients: NCT06112236	University of Zurich	—
Completed	Ferric Carboxymaltose With or Without Phosphate Substitution for the Treatment of Iron Deficiency or Iron Defi NCT05098249	Donat R. Spahn	Phase 4
Unknown	Hypophosphatemia and Bronchiolitis NCT04814641	Hospices Civils de Lyon	—
Unknown	Levels of 'Hypophosphatemia Affect Outcome of Septic Patients in ICU NCT04519762	Ain Shams University	Phase 4
Unknown	Investigation of Hypophosphataemia Following Intravenous Iron NCT04502784	Belfast Health and Social Care Trust	—
Unknown	Simplified Regional Citrate Anticoagulation Protocols for CVVH, CVVHDF and SLED: a Pilot Study NCT03976440	University of Parma	—
Suspended	The Impact of Phosphate Metabolism on Healthy Aging NCT03771105	Yale University	EARLY_Phase 1
Completed	FGF23 and Angiotensin-(1-7) in Hypophosphatemia (GAP) NCT03489993	Wake Forest University Health Sciences	—
Withdrawn	Biomarker for Cystinosis Disease: BioCystinosis (BioCystinosis) NCT02837523	CENTOGENE GmbH Rostock	—
Completed	Open Label Trial Assessing Safety and Efficacy of Burosumab (KRN23), in a Patient With ENS and Hypophosphatemi NCT03581591	Redwood Dermatology Sciences	Phase 3
Completed	Hypophosphatemia as a Predictor in Surgical Resuscitation Sepsis NCT03740802	University Hospital, Brest	—
Completed	Hypophosphatemia as a Predictive Marker of Mortality During Sepsis in ICU NCT03529058	University Hospital, Brest	—
Unknown	Observing the Changes of Fibroblast Growth Factor 23 in Patients of Tumor Induced Osteomalacia NCT01660308	National Taiwan University Hospital	—
Completed	Treatment of Autonomous Hyperparathyroidism in Post Renal Transplant Recipients NCT00975000	Amgen	Phase 3
Terminated	Using Cinacalcet to Treat the Hypophosphatemia of Early Kidney Transplant NCT01011114	Montefiore Medical Center	N/A
Completed	FGF-23 Suppressibility by Calcitonin NCT00688077	Rijnstate Hospital	N/A